- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03532633
Supply With Micronutrients (Purine and Pyrimidine) in Infants: a Prospective and Observational Study
Beobachtungsstudie Zur Versorgung Reif- Und Frühgeborener Mit ausgewählten Mikronährstoffen Wissenschaftliche Untersuchung Bei Minderjährigen
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Collection of:
- cord plasma in preterm and term infants.
- remnants of clinically indicated blood samples of mothers 24 hours before or after birth.
- remnants of clinically indicated blood samples of preterm and term infants during neonatal care.
- breast milk once a weak during neonatal care of the infant.
Determination concentrations of micronutrients by mass spectrometry.
Aim is to compare cord plasma concentrations with postnatal plasma concentrations and to measure concentrations in breast milk to determine the actual supply.
Update September 2020:
The results obtained according to the original protocol revealed a serious sample instability when using remnants of clinical blood samples. Remnants can not be used and therefore the protocol had to be changed. A new approval of the Ethics Committee was obtained and is available to the study team. The following changes for sample collection were implemented: an additional blood sample (2.7ml EDTA blood) is taken from the mothers after approval.The blood samples of premature and newborns (max. 3x 0.2 ml) are obtained when a clinically indicated blood sample is taken. In both cases the serum is frozen immediately within one hour after collection.
Due to these changes, the expected end of the study is postponed to 2021.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Luoghi di studio
-
-
-
Tuebingen, Germania, 72076
- Reclutamento
- University Children's Hospital Tuebingen
-
Contatto:
- Axel Franz, MD
- Numero di telefono: +497071290
- Email: axel.franz@med.uni-tuebingen.de
-
Investigatore principale:
- Axel Franz, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- 23+0-42+6 SSW
Exclusion Criteria:
- congenital malformation, genetic disorders
- metabolic disease of the infant
- missing agreement
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
23-27w
preterm infants 23+0-27+6SSW
|
collection of cord blood
collection of remnant of clinically indicated blood sample
collection of remnant of clinically indicated blood sample.
If not available blood sample is taken after mother agreed
collection of breast milk 1/week during neonatal care (maximum 8 weaks)
|
28-31w
preterm infants 28+0-31+6SSW
|
collection of cord blood
collection of remnant of clinically indicated blood sample
collection of remnant of clinically indicated blood sample.
If not available blood sample is taken after mother agreed
collection of breast milk 1/week during neonatal care (maximum 8 weaks)
|
32-34w
preterm infants 32+0 - 34+6SSW
|
collection of cord blood
collection of remnant of clinically indicated blood sample
collection of remnant of clinically indicated blood sample.
If not available blood sample is taken after mother agreed
collection of breast milk 1/week during neonatal care (maximum 8 weaks)
|
35-36w
preterm infants 35+0-36+6 SSW
|
collection of cord blood
collection of remnant of clinically indicated blood sample
collection of remnant of clinically indicated blood sample.
If not available blood sample is taken after mother agreed
collection of breast milk 1/week during neonatal care (maximum 8 weaks)
|
37-42w
term infants 37+0-42+6
|
collection of cord blood
collection of remnant of clinically indicated blood sample
collection of remnant of clinically indicated blood sample.
If not available blood sample is taken after mother agreed
collection of breast milk 1/week during neonatal care (maximum 8 weaks)
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Concentration of purine and pyrimidine in cord plasma
Lasso di tempo: at birth
|
at birth
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Concentration of purine and pyrimidine in neonatal plasma
Lasso di tempo: at times when a clinically indicated blood sample is taken before discharge home from the initial neonatal hospitalization (at a postnatal age of up to 4-5 months at the most in very preterm infants)
|
at times when a clinically indicated blood sample is taken before discharge home from the initial neonatal hospitalization (at a postnatal age of up to 4-5 months at the most in very preterm infants)
|
Concentration of purine and pyrimidine in breast milk
Lasso di tempo: once a week before discharge home from the initial neonatal hospitalization, maximum 8 weeks
|
once a week before discharge home from the initial neonatal hospitalization, maximum 8 weeks
|
Concentration of purine and pyrimidine in plasma of mothers
Lasso di tempo: 24 hours before and after birth
|
24 hours before and after birth
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- NEO-MICRO
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su cord blood
-
Thomas Klootwyk, MDSignature Biologics, LLC; KLM Solutions, LLCNon ancora reclutamento
-
Saluda Medical Americas, Inc.CompletatoDolore | Mal di schiena | Dolore cronicoStati Uniti
-
Instituto Materno Infantil Prof. Fernando FigueiraHospital Da Mulher do RecifeCompletato
-
The First Affiliated Hospital of Soochow UniversityFirst Affiliated Hospital Xi'an Jiaotong University; Ruijin Hospital; Wuhan Union... e altri collaboratoriReclutamentoTrapianto di cellule staminali emopoietiche aploidentiche | Sangue del cordone ombelicale | Leucemia linfoblastica acuta a cellule TCina
-
Haydarpasa Numune Training and Research HospitalCompletatoDisturbo della coagulazioneTacchino
-
Cerus CorporationReclutamento
-
Tissue Tech Inc.CompletatoUlcere del piede diabeticoStati Uniti, Canada
-
University Hospital, RouenNon ancora reclutamentoEpatite B | Epatite C | AIDSFrancia
-
MicroPhage, Inc.CompletatoSepsi | Batteriemia | Infezione | Infezione da stafilococcoStati Uniti
-
University of UtahAlbert Einstein College of Medicine; University of California, San Francisco; National... e altri collaboratoriCompletato